Advertisement

PharmacoEconomics

, Volume 15, Issue 6, pp 641–641 | Cite as

A Review of Quality of Life in Alzheimer’s Disease

Parts 1 and 2: Issues in Assessing Disease Impact and Drug Effects
  • Marianne Greer
  • Helma Monteban
Correpondence

Keywords

Dementia Adis International Limited Critical Assessment Subjective Quality Additional Criterion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Walker MD, Salek SS, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 1: issues in assessing disease impact. Pharmacoeconomics 1998; 14 (5): 499–530PubMedCrossRefGoogle Scholar
  2. 2.
    Salek SS, Walker MD, Bayer AJ. A review of quality of life in Alzheimer’s disease. Part 2: issues in assessing drug effets. Pharmacoeconomics 1998; 14 (6): 613–27PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 1999

Authors and Affiliations

  • Marianne Greer
    • 1
  • Helma Monteban
    • 1
  1. 1.Corporate Health EconomicsBoehringer IngelheimGermany

Personalised recommendations